comprehensive -WSS

comprehensive

author：explore 2025-09-27 09:46:09 - browse：55

Teleflex announced plans on Wednesday to acquire Palette Life Sciences, the maker of a slate of gel-based products treating urological disorders. The vascular device manufacturer will pay $600 million upfront, and plans to use Palette’s portfolio to treat more urinary tract and reproductive health conditions.

Palette will bring Teleflex an extra $56 million in sales, the company estimated in a press release. Teleflex develops a range of devices, but makes the most money from vascular products like catheters. The company offers just one urological treatment: the UroLift system to relieve an enlarged prostate. With Palette, it will gain five more treatments all built from hyaluronic acid, a stretchy material that’s meant to last longer in the human body.

Palette’s highest-revenue device is Barrigel, which helps protect the rectum from harsh radiation administered to prostate cancer patients. It eases symptoms like bladder inflammation, bleeding, and diarrhea. The device received FDA clearance in May 2022 through the 510(k) process, which allowed Palette to claim the product was equivalent to a rectal radiation protector sold by Boston Scientific. Boston Scientific has sold that device since 2018, when it acquired it by buying the startup Augmenix for $500 million.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How one medical school became remarkably diverse
Next article： White House touts steps to stem shortages of cancer treatments

leisure time

WSS

Boston competes with Raleigh

Regeneron agrees to White House price limits on anti

Investment in vaccine development is lagging, report finds

Zyn nicotine pouches become unlikely player in latest culture war

White House pharmacy plagued with problems, investigation finds

Medicare drug price negotiation legal challenge met with skepticism

focus

comprehensive

entertainment

Tori Bowie and the unacceptable rates of Black maternal death

Why Medicare shouldn’t cover every FDA

Moonlake's readout produced a cash windfall. Risks remain

Acelyrin, a rare IPO success, stumbles in its first big test

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

IRA could hurt research into orphan drugs for rare diseases

Medicare details structure of new drug price negotiation program

New Covid vaccine is recommended for everyone 6 months or older

What does generative AI mean for health care? We asked experts

Syphilis numbers in the United States reach record heights

focus

Vertex non

FDA proposes changes to key medical devices approval pathway

Bernie Sanders is gearing up to subpoena pharma CEOs

FTC sues over Novant Health acquisition of two N.C. hospitals

Wegovy leads to weight loss. Can it treat depression, too?

Philips to halt sales of sleep apnea machines in U.S.

leisure time

hotspot

Wikipedia

leisure time